Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

In the APOLLO trial, first-line treatment with anlotinib plus penpulimab improved progression-free survival and overall survival when compared to sorafenib.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years of age and older and high-risk individuals aged 12-64 years.

Working with an incompletely staffed team more than 25% of the time is associated with greater odds of burnout for physicians, data suggest.

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.

The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.

Rhenium-SCT is an epidermal radionuclide therapy that utilizes a radioisotope-based resin to treat shallow non-melanoma skin ...

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US ...

One thing that hasn’t changed since 2017 is the strong defense of Medicaid from Democrats, hospital executives, and consumer ...

The FDA has approved Welireg (belzutifan) for the treatment of patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma.

The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.